Dr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.
Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.
Safety data on non-clinician-led services have shown a low complication rate
Prompt evaluation and adherence to guidelines for treatment recommendations for lattice retinal degeneration are essential to the preservation of vision and sight.
Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.
It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).
Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).
Physicians can discover, diagnose, document, treat diseases that might go undetected
Chronic cases can be difficult for retina specialists; treatment is satisfying.
This affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching and reference purposes.
Proactive communication and leveraging advanced, yet reliable, technologies to maximize efficiency are essential pillars of success.
Retina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.
The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Real-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.
The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Results from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
ABI-201 aims to prevent dry AMD and other retinal disorders in patients.
Current options, challenges in developing novel therapies.
A retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.
Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.
The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
This article is produced by Roche for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.
Technology brings new tools to those with low vision caused by AMD